Introduction: Certain studies have observed that patients with moyamoya disease (MMD) have cognitive decline after revascularization. Thus, this study analyzed the relationship between cognitive decline and altered cerebral perfusion after revascularization. Methods: Here, 313 adult patients with MMD underwent single unilateral revascularization. First, cognitive function was scored using a Mini-Mental Scale (MMSE) and Montreal cognitive function scale (MoCA) before and 3 months after the operation (superficial temporal artery-middle cerebral artery anastomosis with encephalo-myo-synangiosis). Then, computed tomography perfusion was performed before and 1 week after the operation to assess the cerebral perfusion. Results: Our data showed that cognitive function decreased in 55 cases (17.6%) after revascularization. Furthermore, the incidence of cerebral hyperperfusion (CHP) was significantly higher in the cognitive decline group (49/55) than in the cognitive nondecline group (89.1% vs. 5.4%, p < 0.001). Results also showed that although all 55 patients had postoperative cognitive decline, 47 experienced relative cerebral blood flow (CBF) decrease at a relatively distant area of the anastomosis compared with that before the operation, which was significantly higher than in patients without cognitive decline (85.5% vs. 1.94%, p < 0.001). In addition, 41 patients had a simultaneous occurrence of local CHP and paradoxical CBF decrease at a relatively distant anastomosis area, which indicated the incident of watershed shift (WS). As observed, WS occurred in 74.5% of patients with cognitive decline, significantly higher than in patients without cognitive decline (74.5% vs. 0%, p < 0.0001). Through multiple logistic regression analysis, WS was also observed to be a strong independent risk factor for predicting postoperative cognitive decline 3 months after revascularization (odds ratio 17.780, 95% confidence interval 1.668–18.564; p = 0.017). Conclusion: Therefore, cognitive decline in patients with MMD after revascularization is related to WS, leading to an uneven distribution of CBF.

1.
Suzuki
J
,
Takaku
A
.
Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain
.
Arch Neurol
.
1969
;
20
(
3
):
288
99
. .
2.
Czabanka
M
,
Pena-Tapia
P
,
Scharf
J
,
Schubert
GA
,
Munch
E
,
Horn
P
,
Characterization of direct and indirect cerebral revascularization for the treatment of European patients with moyamoya disease
.
Cerebrovasc Dis
.
2011
;
32
(
4
):
361
9
.
3.
Jeon
JP
,
Kim
JE
,
Cho
WS
,
Bang
JS
,
Son
YJ
,
Oh
CW
.
Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults
.
J Neurosurg
.
2018
;
128
(
3
):
793
9
. .
4.
Guzman
R
,
Lee
M
,
Achrol
A
,
Bell-Stephens
T
,
Kelly
M
,
Do
HM
,
Clinical outcome after 450 revascularization procedures for moyamoya disease
.
J Neurosurg
.
2009
;
111
(
5
):
927
35
.
5.
Zeifert
PD
,
Karzmark
P
,
Bell-Stephens
TE
,
Steinberg
GK
,
Dorfman
LJ
.
Neurocognitive performance after cerebral revascularization in adult moyamoya disease
.
Stroke
.
2017
;
48
(
6
):
1514
7
. .
6.
Kikuta
KI
,
Takagi
Y
,
Nozaki
K
,
Yamada
K
,
Miyamoto
S
,
Kataoka
H
,
Effects of intravenous anesthesia with propofol on regional cortical blood flow and intracranial pressure in surgery for moyamoya disease
.
Surg Neurol
.
2007
;
68
(
4
):
421
4
.
7.
Tu
XK
,
Fujimura
M
,
Rashad
S
,
Mugikura
S
,
Sakata
H
,
Niizuma
K
,
Uneven cerebral hemodynamic change as a cause of neurological deterioration in the acute stage after direct revascularization for moyamoya disease: cerebral hyperperfusion and remote ischemia caused by the “watershed shift”
.
Neurosurg Rev
.
2017
;
40
(
3
):
507
12
.
8.
Hayashi
T
,
Shirane
R
,
Fujimura
M
,
Tominaga
T
.
Postoperative neurological deterioration in pediatric moyamoya disease: watershed shift and hyperperfusion clinical article
.
J Neurosurg Pediatr
.
2010
;
6
(
1
):
73
81
.
9.
Fujimura
M
,
Shimizu
H
,
Inoue
T
,
Mugikura
S
,
Saito
A
,
Tominaga
T
.
Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease: comparative study with non-moyamoya patients using N-Isopropyl-p- I-123 iodoamphetamine single-photon emission computed tomography
.
Neurosurgery
.
2011
;
68
(
4
):
957
64
.
10.
Fujimura
M
,
Inoue
T
,
Shimizu
H
,
Saito
A
,
Mugikura
S
,
Tominaga
T
.
Efficacy of prophylactic blood pressure lowering according to a standardized postoperative management protocol to prevent symptomatic cerebral hyperperfusion after direct revascularization surgery for moyamoya disease
.
Cerebrovasc Dis
.
2012
;
33
(
5
):
436
45
. .
11.
Fujimura
M
,
Tominaga
T
.
Current status of revascularization surgery for moyamoya disease: special consideration for its “Internal Carotid-External Carotid (IC-EC) conversion” as the physiological reorganization system
.
Tohoku J Exp Med
.
2015
;
236
(
1
):
45
53
. .
12.
Hsu
LM
.
Caveats concerning comparisons of change rates obtained with five methods of identifying significant client changes: comment on Speer and Greenbaum (1995)
.
J Consult Clin Psychol
.
1999
;
67
(
4
):
594
8
. .
13.
Kopecek
M
,
Bezdicek
O
,
Sulc
Z
,
Lukavsky
J
,
Stepankova
H
.
Montreal cognitive assessment and mini-mental state examination reliable change indices in healthy older adults
.
Int J Geriatr Psychiatry
.
2017
;
32
(
8
):
868
75
. .
14.
Yun
TJ
,
Cheon
JE
,
Na
DG
,
Kim
WS
,
Kim
IO
,
Chang
KH
,
Childhood moyamoya disease: quantitative evaluation of perfusion MR imaging-correlation with clinical outcome after revascularization surgery
.
Radiology
.
2009
;
251
(
1
):
216
23
.
15.
Hatazawa
J
,
Fujita
H
,
Kanno
I
,
Satoh
T
,
Iida
H
,
Miura
S
,
Regional cerebral blood flow, blood volume, oxygen extraction fraction, and oxygen utilization rate in normal volunteers measured by the autoradiographic technique and the single breath inhalation method
.
Ann Nucl Med
.
1995
;
9
(
1
):
15
21
.
16.
Tashiro
R
,
Fujimura
M
,
Kameyama
M
,
Mugikura
S
,
Endo
H
,
Takeuchi
Y
,
Incidence and risk factors of the watershed shift phenomenon after superficial temporal artery-middle cerebral artery anastomosis for adult moyamoya disease
.
Cerebrovasc Dis
.
2019
;
47
(
3–4
):
178
87
.
17.
Hearne
LJ
,
Mattingley
JB
,
Cocchi
L
.
Functional brain networks related to individual differences in human intelligence at rest
.
Sci Rep
.
2016
;
6
:
32328
. .
18.
Yanagihara
W
,
Chida
K
,
Kobayashi
M
,
Kubo
Y
,
Yoshida
K
,
Terasaki
K
,
Impact of cerebral blood flow changes due to arterial bypass surgery on cognitive function in adult patients with symptomatic ischemic moyamoya disease
.
J Neurosurg
.
2019
;
131
(
6
):
1716
24
.
19.
Dobashi
K
,
Kubo
Y
,
Kimura
K
,
Katakura
Y
,
Chida
K
,
Kobayashi
M
,
De novo cerebral microbleeds and cognitive decline in cerebral hyperperfusion after direct revascularization for adult moyamoya disease
.
J Stroke Cerebrovasc Dis
.
2022
;
31
(
1
):
106166
.
20.
Heros
RC
,
Scott
RM
,
Kistler
JP
,
Ackerman
RH
,
Conner
ES
.
Temporary neurological deterioration after extracranial-intracranial bypass
.
Neurosurgery
.
1984
;
15
(
2
):
178
85
. .
21.
Quon
JL
,
Kim
LH
,
MacEachern
SJ
,
Maleki
M
,
Steinberg
GK
,
Madhugiri
V
,
Early diffusion magnetic resonance imaging changes in normal-appearing brain in pediatric moyamoya disease
.
Neurosurgery
.
2020
;
86
(
4
):
530
7
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.